In the first-line setting, targeted therapy and SSAs were associated with longer PFS than chemotherapy, with surufatinib and lanreotide showing favorable disease control. SDHx pathogenic variant status did not show a clear association with response to TKIs or temozolomide, underscoring the need for validation in larger cohorts.

P2/3, N=235, Recruiting, Hutchmed | Phase classification: P2 --> P2/3 | N=128 --> 235 | Trial completion date: Dec 2025 --> Feb 2030 | Trial primary completion date: Jun 2025 --> Jun 2028

P2/3, N=502, Recruiting, Hutchmed | Trial completion date: Aug 2027 --> May 2028 | Trial primary completion date: Aug 2027 --> May 2028

FGFR1 plays a role in the resistance to immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab...Based on the FGFR1-related research and the active targeting strategy, we believe that modifying the surface of nanomedicines with anti-FGFR1 antibodies (such as OM-RCA-01) is an effective targeted treatment method for tumors with high expression of FGFR1. Although there have been relevant studies confirming the feasibility of this approach, there are challenges in clinical application, especially in terms of maintaining uniform quality during large-scale production. Therefore, we suggest conducting further optimization studies in the future to accelerate the clinical application of such drug delivery systems and provide more efficient and cost-effective options for tumor treatment.

P4, N=350, Recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Recruiting

P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2024 --> Dec 2027

P2, N=35, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P4, N=350, Not yet recruiting, Shanghai Zhongshan Hospital

Exploratory analysis indicates that responders show significantly higher tumor PD-L1 expression than non-responders do, with median tumor proportion scores of 8% and 2%, respectively. The study is registered at ClinicalTrials.gov (NCT05236699).

Increasing evidence suggests that a subset of CCA patients can benefit from multiple tyrosine kinase inhibitors (mTKIs) such as surufatinib...Furthermore, cancer-associated fibroblasts (CAFs) were identified as the major source of IGF1 in CCA microenvironment, essential for IGF1R-driven tumor progression.In summary, the PTPN9-IGF1R axis plays a pivotal role in modulating mTKI sensitivity and tumor progression in CCA. This axis serves as a promising biomarker for identifying potential mTKI beneficiaries and represents a potential therapeutic target to enhance mTKI efficacy and overcome resistance.

From August 2019 to October 2020, he received long-acting octreotide and transarterial chemoembolization (TACE), achieving stable disease...In September 2022, oral surufatinib was initiated but paused in September 2023 due to adverse effects...This case demonstrates that everolimus can induce SSTR re-expression in advanced, SSTR-negative pNETs, offering new therapeutic possibilities. The "induction plus re-evaluation" approach could guide personalized treatment strategies in late-stage pNETs, although further studies are needed to validate this approach.

Surufatinib plus paclitaxel showed promising efficacy and manageable safety as second-line treatment for advanced gastric cancer, especially in patients who had failed prior immunotherapy.